Adam Kibel, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Myovant
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Exlexis
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Insight Diagnositics
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    AstraZeneca
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Bayer
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    General Electric
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other (Oncology)
    Ineligible company:
    advantagene
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Merck
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Other (Specialty Not Specified)
    Ineligible company:
    Bristol-Myers Squibb
    Date added:
    Date updated:
    04/10/2024
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Janssen
    Date added:
    Date updated:
    04/10/2024

Pages

Return to 2022 AUA Annual Meeting Highlights: Prostate Cancer